Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10593768 | 1.00 | CA1 (0.35) | CA1CA2CA4KMT2ACES2 | |
| SCHEMBL23015539 | 1.00 | CA1 (0.35) | CA1CA2CA4KMT2ACES2 | |
| SCHEMBL9539936 | 0.83 | CA1 (0.38) | CA1CA2CA4KMT2A | |
| SCHEMBL7827236 | 0.80 | CA1 (0.33) | CA1CA2CA4KMT2A | |
| SCHEMBL8022375 | 0.79 | CA1 (0.35) | CA1CA2CA4KMT2A | |
| Acetic Acid SCHEMBL10470986 | 0.79 | GLA (0.35) | CA1CA2CA4KMT2ALMNA | |
| SCHEMBL3230995 | 0.76 | KDM4E (0.31) | CA1CA2CA4 | |
| Guaiol SCHEMBL18965701 | 0.72 | LMNA (0.35) | CES2LMNA | |
| Guaiol SCHEMBL14871827 | 0.72 | LMNA (0.35) | CES2LMNA | |
| Guaiol SCHEMBL16207769 | 0.72 | LMNA (0.35) | CES2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358944-B2 | Anxiolytic deuterated compound and medical use thereof | BEIJING JUNKE HUAYUAN MED TECH CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| EP-3611170-B1 | DEUTERATED COMPOUNDS AND MEDICAL USE THEREOF AS ANTIANXIETY AGENTS | BEIJING JUNKE HUAYUAN MED TECH CO LTD (CN) | 2022-01-26 | — | — | EP | disclosed |
| US-20200095219-A1 | ANXIOLYTIC DEUTERATED COMPOUND AND MEDICAL USE THEREOF | BEIJING JUNKE HUAYUAN MED TECH CO., LTD. (CN) | 2020-03-26 | — | — | US | disclosed |
| EP-3611170-A1 | ANTIANXIETY DEUTERATED COMPOUNDS AND MEDICAL USE THEREOF | Jingluweidai Information Consulting Service (Beijing) Co Ltd (CN) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095219-A1 | ANXIOLYTIC DEUTERATED COMPOUND AND MEDICAL USE THEREOF | DRD1, DRD2, DRD4 | CA1 1819/4885CA2 3460/4885CA4 2330/4885 |
| US-11358944-B2 | Anxiolytic deuterated compound and medical use thereof | DRD1, DRD2, DRD4 | CA1 1819/4885CA2 3460/4885CA4 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.